Endometrial cancer originates from malignant tumors of the endometrial glands, also known as corpus uteri cancer, and the vast majority are adenocarcinomas. It is one of the three major malignant tumors of the female reproductive system. In China, endometrial cancer is much lower than cervical cancer, but in some Western developed countries, the disease is higher than cervical cancer and ranks first among gynecological malignant tumors.
The high-incidence age of endometrial cancer is 58 to 61 years, accounting for about 7% of the total number of female cancers and 20% to 30% of gynecological malignant tumors. In recent years, the incidence has shown an increasing trend, and it is approaching or even exceeding cervical cancer. It is related to long-term persistent estrogen stimulation, obesity, hypertension, diabetes, infertility or sterility, and menopause, as well as体质 factors and genetic factors.
The treatment principles of endometrial cancer should be based on the patient's age, physical condition, extent of the lesion, and histological type, choosing an appropriate treatment method. Since most endometrial cancers are adenocarcinomas and are not very sensitive to radiotherapy, treatment is mainly surgical, with other treatments including radiotherapy, chemotherapy, and drug treatments (chemotherapy, hormones, etc.) as comprehensive treatment. Early-stage patients are mainly treated surgically, with adjuvant therapy chosen based on the results of surgical-pathological staging and high-risk factors for recurrence; advanced patients use a comprehensive treatment approach including surgery, radiotherapy, and drug treatment.